donepezil

GPTKB entity

Statements (55)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:administered_by oral tablet
gptkbp:approves gptkb:1996
gptkb:European_Union
gptkb:United_States
gptkbp:atccode N06 DA02
gptkbp:available_as_generic gptkb:Yes
gptkbp:brand gptkb:Aricept
gptkbp:casnumber 120014-06-4
gptkbp:category gptkb:C
gptkbp:chemical_formula C24 H29 NO3
gptkbp:class Cognitive enhancer
gptkbp:clinical_trial Phase III
gptkbp:composed_by gptkb:chemical_compound
gptkbp:contraindication severe liver disease
severe lung disease
allergy to donepezil
gptkbp:developed_by gptkb:Pfizer
gptkb:Eisai
gptkbp:dosage_form 5 mg tablet
10 mg tablet
23 mg tablet
gptkbp:first_synthesis_year gptkb:1983
https://www.w3.org/2000/01/rdf-schema#label donepezil
gptkbp:impact_on_behavior reduces behavioral symptoms
gptkbp:impact_on_cognition improves cognitive function
gptkbp:impact_on_daily_living improves daily living activities
gptkbp:interacts_with NSAIDs
beta-blockers
anticholinergic drugs
certain antidepressants
gptkbp:is_monitored_by monitor for side effects
regular cognitive assessments
gptkbp:legal_status Prescription only
gptkbp:lifespan 70 hours
gptkbp:long_term_use_effect tolerance may develop
gptkbp:marketed_as gptkb:Aricept
gptkbp:mechanism_of_action acetylcholinesterase inhibitor
gptkbp:metabolism liver
gptkbp:patent_expiration_year gptkb:2010
gptkbp:research_focus gptkb:neurodegenerative_diseases
Alzheimer's disease treatment
dementia treatment
gptkbp:rounds urine
feces
gptkbp:side_effect fatigue
nausea
diarrhea
insomnia
muscle cramps
gptkbp:symptoms none reported
gptkbp:used_for gptkb:neurodegenerative_diseases
gptkbp:weight 379.49 g/mol
gptkbp:bfsParent gptkb:Aricept
gptkbp:bfsLayer 6